Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

A recombinant flu vaccine (Flublok) contains no eggs and was recently approved for use in individuals aged 9 years or older ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

Researchers conducted a meta-analysis of 16 randomised clinical trials comparing inactivated high-dose (60 µg haemagglutinin antigen load per strain) and standard-dose (15 µg haemagglutinin antigen ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Sep. 11, 2024 — Avian influenza A (H5N1) virus, which spread to cattle and infected 14 people this year, was detected using virome sequencing in the wastewater of 10 Texas ...

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Moderna's experimental flu vaccine demonstrated superior efficacy compared to standard flu vaccines in late-stage trials.

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...